{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:09:01Z","timestamp":1791976141315,"version":"4.4.0"},"reference-count":32,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2015,10,12]],"date-time":"2015-10-12T00:00:00Z","timestamp":1444608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:p>Prolonged survival in patients with chronic myeloid leukemia treated with BCR\u2010ABL1\u2010targeted tyrosine kinase inhibitors allows consideration of parenthood for patients on chronic therapy, but there are limited data about the effects of dasatinib on pregnancy. Pregnancy\u2010related outcomes in dasatinib\u2010treated patients or their partners reported to Bristol\u2013Myers Squibb from clinical trials or healthcare providers through December 2013 were reviewed. Outcomes were available in 46\/78 dasatinib\u2010treated women (59%) and 33\/69 partners of dasatinib\u2010treated men (48%). Fifteen women (33%) delivered a normal infant; 18 (39%) and 8 (17%) had an elective or spontaneous abortion; and 5 (11%) had an abnormal pregnancy. There were 7 reports of fetal\/infant abnormalities (encephalocele, renal tract abnormalities, and hydrops fetalis). Thirty of 33 (91%) infants fathered by dasatinib\u2010treated men were reported normal at birth. Also, animal studies evaluated the impact of dasatinib on fertility, embryo\u2010fetal toxicity, and development, suggesting that dasatinib may be a selective developmental toxicant. The outcomes of most pregnancies conceived by men treated with dasatinib were normal, but due to the small number of cases, further monitoring is required. Significant effects on pregnancy outcomes in women treated with dasatinib were found, supporting current recommendations that women avoid becoming pregnant during dasatinib treatment and be informed of fetal risks. Am. J. Hematol. 90:1111\u20131115, 2015. \u00a9 2015 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.24186","type":"journal-article","created":{"date-parts":[[2015,9,8]],"date-time":"2015-09-08T16:41:09Z","timestamp":1441730469000},"page":"1111-1115","source":"Crossref","is-referenced-by-count":120,"title":["The impact of dasatinib on pregnancy outcomes"],"prefix":"10.1002","volume":"90","author":[{"given":"Jorge E.","family":"Cortes","sequence":"first","affiliation":[{"name":"Department of Leukemia University of Texas M.D. Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Abruzzese","sequence":"additional","affiliation":[{"name":"Hematology, S. Eugenio Hospital Tor Vergata University Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Chelysheva","sequence":"additional","affiliation":[{"name":"Federal State\u2010Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation Moscow Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mausumee","family":"Guha","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers Squibb Princeton New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Wallis","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers Squibb Princeton New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane F.","family":"Apperley","sequence":"additional","affiliation":[{"name":"Centre for Haematology, Imperial College London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,10,12]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.6557"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-114900"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2014.028"},{"key":"e_1_2_7_5_1","unstructured":"Bristol\u2010Myers Squibb Company.Sprycel (dasatinib) [prescribing information]. Princeton NJ 2015."},{"key":"e_1_2_7_6_1","unstructured":"Novartis Pharmaceuticals Corporation.Gleevec (imatinib) [prescribing information]. East Hanover NJ 2015."},{"key":"e_1_2_7_7_1","unstructured":"Novartis Pharmaceuticals Corporation.Tasigna (nilotinib) [prescribing information]. East Hanover NJ 2015."},{"key":"e_1_2_7_8_1","unstructured":"Pfizer Inc.Bosulif (bosutinib) [prescribing information]. New York NY 2014."},{"key":"e_1_2_7_9_1","unstructured":"Ariad Pharmaceuticals Inc.Iclusig (ponatinib) [prescribing information]. Cambridge MA 2014."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.07.020"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-2-42"},{"key":"e_1_2_7_12_1","first-page":"112","article-title":"Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib","author":"Cortes J","year":"2008","journal-title":"Blood"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.811240"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-010-1501-6"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.05.2010.2975"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/136252"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.497982"},{"key":"e_1_2_7_18_1","first-page":"128","article-title":"Two successful successive pregnancies in a woman with CML treated with dasatinib and temporary peg\u2010interferon","volume":"10","author":"Dine G","year":"2013","journal-title":"J US China Med Sci"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e328352a8fe"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198807283190401"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7251.1708"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.23014"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.09.012"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10935"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.022764"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aanat.2008.01.001"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3097"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2011.1"},{"key":"e_1_2_7_29_1","first-page":"388","article-title":"Development of the calyceal system in the human fetus","volume":"16","author":"Itatani H","year":"1979","journal-title":"Invest Urol"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ydbio.2008.10.012"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1242\/dev.124.14.2691"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1415"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2004.05.087"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24186","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24186","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T11:24:50Z","timestamp":1695554690000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1002\/ajh.24186"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24186","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,12]]}}}